Ado-trastuzumab emtansine (T-DM1) for a case of HER2-amplified metastatic extramammary Paget's disease of scrotum: Clinical next-generation sequencing for precision medicine
Saved in:
Main Authors: | Chih-Yu Chen (Author), Chien-Ping Chiang (Author), Li-Chun Lin (Author), Hong-Wei Gao (Author), Wei-Ming Wang (Author), Ping-Yin Chang (Author) |
---|---|
Format: | Book |
Published: |
Wolters Kluwer Medknow Publications,
2020-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Whether HER2-positive non-breast cancers are candidates for treatment with Ado-trastuzumab emtansine?
by: Azadeh Moghaddas, et al.
Published: (2016) -
Implementation of Systematic Bioanalysis of Antibody-Drug Conjugates for Preclinical Pharmacokinetic Study of Ado-Trastuzumab Emtansine (T-DM1) in Rats
by: Eun-Jeong Jeon, et al.
Published: (2023) -
Retrospective Observational Study of Outcomes in HER2-Positive Metastatic Breast Cancer (mBC) Patients Treated with Ado-Trastuzumab Emtansine (T-DM1) and Subsequent Treatments After T-DM1 in the United States
by: Neelima Denduluri, et al.
Published: (2022) -
Extramammary Paget disease of the axilla and scrotum in a Caucasian man
by: Christina Dai, MD, et al.
Published: (2022) -
Cost-effectiveness analysis of trastuzumab deruxtecan versus trastuzumab emtansine for HER2-positive breast cancer
by: Jiangping Yang, et al.
Published: (2022)